Cargando…

Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavi...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbone, Michele, Lednicky, John, Xiao, Shu-Yuan, Venditti, Mario, Bucci, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832772/
https://www.ncbi.nlm.nih.gov/pubmed/33422679
http://dx.doi.org/10.1016/j.jtho.2020.12.014
_version_ 1783641909776875520
author Carbone, Michele
Lednicky, John
Xiao, Shu-Yuan
Venditti, Mario
Bucci, Enrico
author_facet Carbone, Michele
Lednicky, John
Xiao, Shu-Yuan
Venditti, Mario
Bucci, Enrico
author_sort Carbone, Michele
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic—this has caused unnecessary anxiety. Individuals more than 65 years old, those affected by obesity, diabetes, asthma, or are immune-depressed owing to cancer and other conditions, are at a higher risk of hospitalization and of dying of COVID-19. Healthy individuals younger than 40 years very rarely die of COVID-19. Estimates of the COVID-19 mortality rate vary because the definition of COVID-19–related deaths varies. Belgium has the highest death rate at 154.9 per 100,000 persons, because it includes anyone who died with symptoms compatible with COVID-19, even those never tested for SARS-CoV-2. The United States includes all patients who died with a positive test, whether they died because of, or with, SARS-CoV-2. Countries that include only patients in which COVID-19 was the main cause of death, rather than a cofactor, have lower death rates. Numerous therapies are being developed, and rapid improvements are anticipated. Because of disinformation, only approximately 50% of the U.S. population plans to receive a COVID-19 vaccine. By sharing accurate information, physicians, health professionals, and scientists play a key role in addressing myths and anxiety, help public health officials enact measures to decrease infections, and provide the best care for those who become sick. In this article, we discuss these issues.
format Online
Article
Text
id pubmed-7832772
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Association for the Study of Lung Cancer. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78327722021-01-26 Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For Carbone, Michele Lednicky, John Xiao, Shu-Yuan Venditti, Mario Bucci, Enrico J Thorac Oncol Special Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic—this has caused unnecessary anxiety. Individuals more than 65 years old, those affected by obesity, diabetes, asthma, or are immune-depressed owing to cancer and other conditions, are at a higher risk of hospitalization and of dying of COVID-19. Healthy individuals younger than 40 years very rarely die of COVID-19. Estimates of the COVID-19 mortality rate vary because the definition of COVID-19–related deaths varies. Belgium has the highest death rate at 154.9 per 100,000 persons, because it includes anyone who died with symptoms compatible with COVID-19, even those never tested for SARS-CoV-2. The United States includes all patients who died with a positive test, whether they died because of, or with, SARS-CoV-2. Countries that include only patients in which COVID-19 was the main cause of death, rather than a cofactor, have lower death rates. Numerous therapies are being developed, and rapid improvements are anticipated. Because of disinformation, only approximately 50% of the U.S. population plans to receive a COVID-19 vaccine. By sharing accurate information, physicians, health professionals, and scientists play a key role in addressing myths and anxiety, help public health officials enact measures to decrease infections, and provide the best care for those who become sick. In this article, we discuss these issues. International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2021-04 2021-01-07 /pmc/articles/PMC7832772/ /pubmed/33422679 http://dx.doi.org/10.1016/j.jtho.2020.12.014 Text en © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Special Article
Carbone, Michele
Lednicky, John
Xiao, Shu-Yuan
Venditti, Mario
Bucci, Enrico
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
title Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
title_full Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
title_fullStr Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
title_full_unstemmed Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
title_short Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
title_sort coronavirus 2019 infectious disease epidemic: where we are, what can be done and hope for
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832772/
https://www.ncbi.nlm.nih.gov/pubmed/33422679
http://dx.doi.org/10.1016/j.jtho.2020.12.014
work_keys_str_mv AT carbonemichele coronavirus2019infectiousdiseaseepidemicwherewearewhatcanbedoneandhopefor
AT lednickyjohn coronavirus2019infectiousdiseaseepidemicwherewearewhatcanbedoneandhopefor
AT xiaoshuyuan coronavirus2019infectiousdiseaseepidemicwherewearewhatcanbedoneandhopefor
AT vendittimario coronavirus2019infectiousdiseaseepidemicwherewearewhatcanbedoneandhopefor
AT buccienrico coronavirus2019infectiousdiseaseepidemicwherewearewhatcanbedoneandhopefor